Altered heme pathway regulation and drug metabolizing enzyme system in a mouse model of hepatocarcinogenesis: Effect of veronal

General Pharmacology

Volumn 29, Issue 4, 1997, Pages 569-573

  Gerez, Esther ^a   Vazquez, Elba ^a   Caballero, Fabiana ^a   Polo, César ^a   Batlle, Alcira ^a  

^a Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

Author keywords

Azo dye; Drug metabolizing enzyme system; Heme metabolism; Hepatocarcinogenesis; Porphyrinogen drug

Indexed keywords

4 DIMETHYLAMINOAZOBENZENE; 5 AMINOLEVULINATE SYNTHASE; BARBITAL; CYTOCHROME P450; HEME OXYGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEME SYNTHESIS; LIVER CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030879634     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(96)00574-5     Document Type: Article

References (27)

1. Aström A., De Pierre J., Eriksson L. Characterization of drug metabolizing systems in hyper-plastic nodules from the livers of rats receiving 2-acetylaminofluorene in their diet. Carcinogenesis (Lond.). 4:1983;577-581.
2. Brady A., Hasmall R., Elcombe B. Comparison of the effects of griseofulvin and dihydropyridines on ferrochelatase mouse and rat hepatocytes. Toxicol. in Vitro. 7:1993;587-593.
3. Cameron R., Sweeney G., Jones K., Lee G., Farber E. A relative deficiency of cytochrome P450 and aryl hydrocarbonbenzo (α) pyrene hydroxylase in hyperplastic nodules induced by 2-acetylaminofluorene in rat liver. Cancer Res. 36:1976;3888-3893.
4. Chance B., Maehly A. Assay of catalases and peroxidases. Chance E., Maehly A. Methods in Enzymology Vol. 2. 1955;764-768 Academic Press, New York.
5. El-Mouelhi M., Didolkar M., Elias E., Guengerich F., Kauffman F. Hepatic drug metabolizing enzymes in primary and secondary tumors of human liver. Cancer Res. 47:1987;460-466.
6. Farber E. Cellular biochemistry of the stepwise development of cancer with chemicals. G.H.A. Clowes Memorial Lectures Cancer Res. 44:1984;5463-5474.
7. Gindi T., Ghazarian D., Deitch D., Farber E. An origin of presumptive preneoplastic foci and nodules from hepatocytes in chemical carcinogenesis in rat liver. Cancer Lett. 83:1994;75-80.
8. Habib S., Srikanth N., Scappaticci F., Faletto M., Macculbin A., Farber E., Ghoshal A., Gurtoo H. Altered expression of cytochrome P450 mRNA during chemical-induced hepatocarcinogenesis and following partial hepatectomy. Toxicol. Appl. Pharmacol. 124:1994;139-148.
9. Habig W., Pabst M., Jakoby W. Glutathione-S-transferases. the first enzymatic step in mercapturic acid formation J. Biol. Chem. 249:1974;7130-7139.
10. Harrison D. Molecular mechanism of drug resistance in tumors. J. Pathol. 175:1995;7-12.
11. Kanduc D., Aresta A., Farber E. Hyper-methylation of replicating hepatic DNA following N-methyl-N-nitrosourea administration. Int. J. Cancer. 58:1994;436-439.
12. Kitagawa T., Pitot H., Miller E., Miller J. Promotion by dietary phenobarbital of hepatocarcinogenesis by 2-methyl-N,N-dimethyl-4-aminoazobenzene in the rat. Cancer Res. 39:1979;112-115.
13. Knox W. L-Tryptophan 2,3-dioxygenase (trytophanpyrrolase) (rat liver). Methods Enzymol. 17:1970;415-417.
14. Lowry O., Rosebrough N., Farr A., Randall R. Protein measurement with the Folin-phenol reagent. J. Biol Chem. 193:1951;265-275.
15. Marver H., Tschudy D., Perlroth M., Collins A. δ-Aminolevulinic acid synthetase I. studies in liver homogenates J. Biol. Chem. 241:1966;2803-2809.
16. Miller E., Miller J. The metabolism of chemical carcinogens to reactive electrophiles and their possible mechanism of action in carcinogenesis. Searle C. E. Chemical Carcinogens. 1976;737-762 American Chemical Society, Washington DC.
17. Omura T., Sato R. The carbon monoxide binding pigment of liver microsomes. J. Biol. Chem. 239:1964;2370-2378.
18. Peraino C., Fry R., Staffeldt E. Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene. Cancer Res. 31:1971;1506-1512.
19. Polo C., Vazquez E., Caballero F., Gerez E., Batlle A. Heme biosynthesis pathway regulation in a model of hepatocarcinogenesis pre-initiation. Comp. Biochem. Physiol. 103B:1992;251-256.
20. Salonpää P., Krause K., Pelkonen O. Up-regulation of CyP2A5 expression by porphyrinogenic agents in mouse liver. Naunyn-Schmideberg's Arch. Pharmac. 351:1995;446-452.
21. Stout D., Becker F. Alteration of the ability of liver microsomes to activate N-2-fluorencylacetamide to mutagen of Salmonella thypimurium during hepatocarcinogenesis. Cancer Res. 38:1978;2274-2278.
22. Stout D., Becker F. Heme enzyme pattern in rat liver nodules and tumors. Cancer Res. 47:1987;963-966.
23. Tatematsu M., Tsuda H., Shibata M., Masui T., Asamoto S., Ito N. Placental type of glutathione S-transferase (GST-P) as a new marker for hepatocarcinogenesis. Proc. Am. Assoc. Cancer Res. Abstracts. 27:1986;100.
24. Toyokuni S., Okamoto K., Yodoi J., Hiai H. Persistent oxidative stress in cancer. FEBS Letters. 358:1995;1-3.
25. Tredaniel J., Zalcman G., Douriez E. Genes and enzymes involved in carcinogen metabolism. Bull. Cancer. 82:1995;S77-S84.
26. Waxman D., Azaroff L. Phenobarbital induction of cytochrome P450 gene expression. Biochem. J. 281:1992;577-592.
27. Yoshida T., Kikuchi G. Purification and properties of heme oxygenase from pig spleen microsomes. J. Biol. Chem. 253:1978;4224-4229.